Dark
Light
Today: February 6, 2025
December 21, 2023
1 min read

Boyd Street Ventures backs game-changer, Cadenza Bio’s biotech breakthrough!

Boyd Street Ventures has announced an investment in biotech company Cadenza Bio. The company focuses on developing small molecules for demyelinating and inflammatory diseases, with a specific focus on multiple sclerosis (MS). Cadenza Bio aims to halt the progression of MS, restore function, and improve the quality of life for patients. The company holds an exclusive license to technology developed through a research collaboration between Dr. John Katzenellenbogen of the University of Illinois Urbana-Champaign and Dr. Seema Tiwari-Woodruff of the University of California, Riverside. Boyd Street Ventures is impressed with the potential of Cadenza Bio and believes that their participation will play a meaningful role in the company’s growth and development.

Previous Story

The life sciences champions: Top 5 mighty venture capital movers!

Next Story

Venture group secures colossal $389M fund, championing schizophrenia and vaccines!

Latest from Blog

VCFA Group Closes $1225M Venture Partners VII Fund

TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in

Top AI Trends and Startups Shaping 2025 and Beyond

“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI
Go toTop